Hisamitsu Pharmaceutical Management
Management criteria checks 1/4
Hisamitsu Pharmaceutical's CEO is Kazue Nakatomi, appointed in May 2015, has a tenure of 10.5 years. directly owns 0.35% of the company’s shares, worth $6.62M. The average tenure of the management team and the board of directors is 1.8 years and 5.5 years respectively.
Key information
Kazue Nakatomi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.5yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.8yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO
Kazue Nakatomi (53 yo)
Mr. Kazuhide Nakatomi, also known as Kazue, serves as Chief Executive Officer since May 2019, President since May 2015 & Representative Director since May 2007 at Hisamitsu Pharmaceutical Co. Inc. and serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.5yrs | no data | 0.35% $ 6.6m | |
| Managing Executive Officer | 1.8yrs | no data | no data | |
| Exe Officer of Legal Affairs | 11.5yrs | no data | 0.0071% $ 133.5k | |
| Executive Officer of Public Relations | 1.8yrs | no data | no data | |
| Executive Officer | no data | no data | 0.0042% $ 80.1k | |
| Senior Managing Executive Officer | 1.8yrs | no data | no data | |
| MD, Executive Officer & Director | no data | no data | 0.0099% $ 187.0k | |
| Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | no data | no data | 0.0085% $ 160.2k | |
| Senior Executive Officer & GM of Pharmaceutical Business Division | no data | no data | no data | |
| Senior Executive Officer and GM of the Pharmaceuticals & Cosmetics Division | no data | no data | no data | |
| Executive Officer and GM of the Regional Mass Sales Dept of Pharmaceuticals & Cosmetics Division | 1.8yrs | no data | no data | |
| Executive Officer & Director | less than a year | no data | no data |
Experienced Management: HTSU.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18.5yrs | no data | 0.35% $ 6.6m | |
| Exe Officer of Legal Affairs | 11.5yrs | no data | 0.0071% $ 133.5k | |
| Executive Officer | 4.5yrs | no data | 0.0042% $ 80.1k | |
| MD, Executive Officer & Director | 12.5yrs | no data | 0.0099% $ 187.0k | |
| Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director | 11.5yrs | no data | 0.0085% $ 160.2k | |
| Executive Officer & Director | less than a year | no data | no data | |
| Executive Officer | less than a year | no data | no data | |
| Chairman of Auditors | 17.5yrs | no data | 0.32% $ 6.1m | |
| Part-time Outside Independent Director | 5.5yrs | no data | 0.0028% $ 53.5k | |
| Part-time Outside Independent Director | 5.5yrs | no data | no data | |
| Part Time Outside Independent Director | 2.5yrs | no data | no data | |
| Part-Time Outside Director | less than a year | no data | no data |
Experienced Board: HTSU.F's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 22:48 |
| End of Day Share Price | 2025/08/21 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2025/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hisamitsu Pharmaceutical Co., Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |